Uncategorized

Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February.

Nicox SA announced the signature of an agreement granting Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing, exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or

Sana Biotechnology, Inc. announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share.

Strong growth and pipeline momentum with three new medicines approved since the third quarter

PARIS, FRANCE, 8 February 2024 – Ipsen, a global specialty-care biopharmaceutical company, presents its financial results for the year and final quarter of 2023.

Tenax Therapeutics, Inc. announced that the first patient has enrolled in the Company’s Phase 3 LEVEL Study.

Kyverna Therapeutics, Inc. announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share.

Academic and industry jobs are distinguished by their approaches to collaboration and exploratory research, among other factors.

FDA backing for the Wavewriter SCS systems allows the company to challenge Abbott and Nevro.

The U.K. health assessor the National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix 360 (formerly known as e-Stroke) to help clinical decision making in stroke.